Thymogen (Glu-Trp)

Thymogen is a synthetic dipeptide, L-glutamyl-L-tryptophan (Glu-Trp), developed as a short-peptide immunomodulator. It belongs to the family of thymic peptide preparations associated with the St. Petersburg school of bioregulation, where it was conceived as a defined, synthesizable successor to the earlier thymus-extract preparation thymalin. In Russia and several neighboring countries it has been used as an immunostimulant, formulated as a nasal spray and an injectable solution; it holds no marketing authorization in the United States or European Union.

Thymogen emerged from decades of thymic-peptide research led by Vladimir Khavinson and colleagues, who worked to reduce complex thymus extracts to their shortest active fragments. The reasoning was that a two-amino-acid sequence would be far easier to characterize, synthesize, and standardize than a heterogeneous glandular extract. That program produced Thymogen (Glu-Trp) as a purported immunoactive dipeptide. Almost all of the primary literature originates from this single research tradition and is published predominantly in Russian-language journals, which is the central caveat for interpreting any claim about it.

The proposed mechanism is immunomodulation rather than direct immunostimulation: Thymogen is described in the originating literature as influencing T-lymphocyte differentiation and helping normalize the balance of immune signaling, nudging an under- or over-active response toward baseline. Consistent with the broader "peptide bioregulator" hypothesis advanced by the same group, some accounts propose effects on gene expression. These mechanisms are drawn largely from in vitro and animal work within one research lineage and have not been independently mapped in the detail that would let an outside reader evaluate them confidently.

The published evidence is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research.

This table summarizes commonly discussed claims and how the published evidence weighs in.

In the published and regional-clinical literature, Thymogen has been given as a nasal spray and as an intramuscular injection in short courses. Because it is a dipeptide with very rapid plasma turnover, the proposed activity is attributed to signaling rather than sustained systemic levels. None of these routes has been validated in independent controlled human trials.

Thymogen occupies a specific niche: a chemically simple, well-defined synthetic dipeptide with a genuine history of clinical use in one part of the world, and a correspondingly narrow international evidence base. The immunological rationale is coherent and the regional track record is real, but the controlled, independently replicated trials that would let the wider medical community judge efficacy have not been done. For readers, the substantive questions are about evidence lineage and regulatory status rather than mechanism detail. Thymogen is discussed alongside related compounds in our overview of the Khavinson short peptides, which sets its evidence tradition in context.